Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510783 · ClinicalTrials.gov registry record · Phase 4
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 158
- Enrollment target
NCT00510783 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 158 participants.
The verdict
NCT00510783, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 158 participants
- Enrollment target
Study Summary
This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a history of seizures can be involved. The patient must present to the emergency department within 4 hours of a seizure. The purpose of this study is to compare these three drugs, phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are looking to see if these drugs can prevent another seizure in the next 24 hours. We are also looking for any possible side effects.
Interventions
- DRUG Keppra
- DRUG Fosphenytoin
- DRUG Dilantin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510783
The ClinicalTrials.gov registry entry for NCT00510783 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Keppra is the first listed.
NCT00510783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510783 about?
NCT00510783 is a clinical study titled "IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures". This study is looking at three seizure medicines. Patients with seizures are usually treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be given this way also. This study will compare...
What is the current status of trial NCT00510783?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 158 participants. The study started on 2007-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00510783?
The interventions under investigation include: Keppra (DRUG), Fosphenytoin (DRUG), Dilantin (DRUG).
Who is sponsoring clinical trial NCT00510783?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.